The Future of Swedish & Danish Life Science – keynote speaker introduction

Meet leading voices shaping the future of Nordic life science, such as Søren Møller, Managing Partner, Seed Investments at Novo Holdings, at the 15th edition of The Future of Swedish & Danish Life Science on 23 April at Medicon Village.

His presentation will outline Novo Holdings’ investment approach to building Nordic biotech companies, with strong investment syndicates and a sufficient capital base for drug development.

Prior to joining Novo Holdings, Søren served as Global Manager of Genomics at Novozymes. Before that, he was CSO and VP of R&D at Exiqon. Earlier in his career, Søren worked in cancer drug development as Head of Lead Identification at BioImage and as a research scientist at Novo Nordisk. He serves on the boards of directors of Reapplix, Orbis Medicines and NorthSea Therapeutics, and has been a board member of Danish Biotech and Active Owners Denmark since 2008.

Expect a highly relevant seminar programme at this well-established life science congress, bringing together hundreds of decision-makers, innovators and thought leaders from across Sweden and Denmark for a high-impact day of insight, interaction and opportunity.

Alongside the stage programme, you will find a vibrant exhibition featuring leading life science organisations, excellent networking opportunities, and structured one-to-one partnering meetings designed to spark new collaborations and drive growth.

Free admission for members of Medicon Village. More information and registration